Autogenomics

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said. 

The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Korea Institute of Science and Technology has been awarded

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics filed with the US Securities and Exchange Commission to officially withdraw a planned initial public offering.

Having garnered 510(k) regulatory clearance in August for its rapid-analysis CYP2C19 genetic test, Spartan Bioscience will continue to work with the US Food and Drug Administration to try to gain the agency's okay for marketing the test in the point-of-care setting.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.